Étiquette : schizophrénie

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, décembre 2020. (4e version, décembre 2020....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 29 7 - Cannabinoïdes et Sommeil : 30 - 31 8 - Cannabinoïdes et addiction au Cannabis : 32 - 39 9 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 40 - 54 10 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59 11 - Cannabinoides et Hyperactivité [...]

Lire la suite

Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective, Koby Cohen and Aviv M. Weinstein, 2018

Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective Koby Cohen and Aviv M. Weinstein Frontiers in Public Health, 2018, Volume 6 | Article 162 doi : 10.3389/fpubh.2018.00162 There is a growing use of novel psychoactive substances containing synthetic cannabinoids. Synthetic cannabinoid products have effects similar to those of natural cannabis, yet, these drugs are more potent and dangerous, and have been associated with dangerous adverse effects. Here, we review current literature on the epidemiology, acute, and chronic effects of synthetic and natural cannabinoid-based drugs. Synthetic drugs contain a mixture of psychoactive compounds that mostly bind cannabinoid receptors with [...]

Lire la suite

Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia, Nathan A. Gillespie, Kenneth S. Kendler, 2020

Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry,  Published online November 4, 2020   Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]

Lire la suite

The role of cannabinoid transmission in emotional memory formation : implications for addiction and schizophrenia, Huibing Tan et al., 2014

The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia Huibing Tan, Tasha Ahmad, Michael Loureiro, Jordan Zunder and Steven R. Laviolette Frontiers in Psychiatry, 2014,Vol 5, Article 73, 1-12 doi : 10.3389/fpsyt.2014.00073   Emerging evidence from both basic and clinical research demonstrates an important role for endo-cannabinoid (ECB) signaling in the processing of emotionally salient information, learning, and memory. Cannabinoid transmission within neural circuits involved in emotional processing has been shown to modulate the acquisition, recall, and extinction of emotionally salient memories and importantly, can strongly modulate the emotional salience of incoming sensory information. Two neural regions in particular, the [...]

Lire la suite

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale, Dr Christian SUEUR, GRECC, septembre 2020.

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale   Dr Christian SUEUR, GRECC, septembre 2020.     Psychédéliques : neurobiologie et psychopharmacologie : 1 - 3 Psychédéliques et réactions indésirables : 4 - 5 Psychédéliques et psychopathologie : 6 - 7 Psychédéliques et « psychoses induites » : 8 - 9 Psychédéliques et “Flash Backs” (Hallucinogen-Persisting Perception Disorders) : 10 - 11 Psychédéliques et « Bad trip » : 11 Psychédéliques et Réduction des risques : 12  

Lire la suite

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ?, Robin M. Murray et al., 2013

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ? Robin M. Murray, Alessandra Paparelli, Paul D. Morrison, Arianna Marconi, and Marta Di Forti American Journal of Medical Genetics, Part B, 2013, 162B, 661–670. Doi : 10.1002/ajmg.b.32177   When drug-induced psychoses were first identified in the mid- 20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug-induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with [...]

Lire la suite

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment, Tibor Stark, 2020,

Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment Tibor Stark, Martina Di Bartolomeo, Roberta Di Marco, Eva Drazanova, Chiara Bianca Maria Platania, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Claudio D'Addario, Lucie Kratka, Vladimir Pekarik, Fabiana Piscitelli, Zuzana Babinska, Julia Fedotova, Giovanni Giurdanella, Salvatore Salomone, Alexandra Sulcova, Claudio Bucolo, Carsten T.Wotjak, Zenon Starcuk Jr, Filippo Drago, Raphael Mechoulam, Vincenzo Di Marzo, Vincenzo Micale Biochemical Pharmacology, April 2020, 1-12. doi : 10.1016/j.bcp.2020.114004     Un excellent article international (République Tchèque, Allemagne, Italy, Russie, Israel, Canada), avec la plus grande plume de la recherche sur les cannabinoïdes (Mechoulam, Di Marzo...) qui [...]

Lire la suite

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia, Fernanda F. Peres et al., 2018

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia Fernanda F. Peres, Mariana C. Diana, Raquel Levin, Mayra A. Suiama, Valéria Almeida, Ana M. Vendramini, Camila M. Santos, Antônio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abílio Frontiers in Pharmacology, 2018, 9, article 901. Doi : 10.3389/fphar.2018.00901   Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able to prevent the emergence of schizophrenia would therefore represent an enormous progress. Here, we investigated whether treatment with cannabidiol (CBD – a compound of Cannabis sativa that [...]

Lire la suite

What to Know About Peyote Use, Buddy T., VeryWellMind.com, 2020

What to Know About Peyote Use By   Buddy T Medically reviewed by   Steven Gans, MD VeryWell Mind.com, Updated on February 14, 2020 https://www.verywellmind.com/how-long-does-peyote-stay-in-your-system-80310 kedsirin jaidee / Getty Images   Peyote (Lophophora williamsii or Lophophora diffusa) is a small, spineless cactus that is found in the southwest United States, northern Mexico and Peru. The plant has been used for about six thousand years by native tribes for religious and healing purposes. Peyote's principal active ingredient is mescaline, a psychedelic compound that can also be man-made through chemical synthesis.1 The peyote buttons, protrusions found on the tops of the cactus plants, are usually dried and then chewed or [...]

Lire la suite

Cannabis consumption and the risk of psychosis, Alice Mulè et al., 2017

Cannabis consumption and the risk of psychosis Alice Mulè, Lucia Sideli, Giuseppe Colli, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray Evidence-based Psychiatric Care, 2017, 3, 25-31   Enfin, un article récent (novembre 2018) explorant la co-occurence "consommation de cannabis / troubles "psychotique"", qui plus est international (anglo-italien), et comprenant, parmi les signataires, les célèbres Robin Murray du Kings Collège londonien, et Marta Di Forti de l'Université de Palerme, qui énonce clairement l'incapacité épidémiologique à établir un lien de causalité entre "consommation de cannabis et éclosion de troubles "psychotique"" !!! : "Conclusions : The [...]

Lire la suite